BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Business

  Veloxis Pharma And Endo Ventures Limited Jointly Announce Agreement For Paladin Labs To Commercialize Envarsus XR In Canada

  June 5, 2017

   · 

  3 min read
• Pharm Country

  Nabriva Announces Webcast Of Analyst & Investor Day On June 19, 2017

  June 5, 2017

   · 

  4 min read
• Drug Development

  Updated Data From KEYNOTE-024 Show Continued Overall Survival Benefit Of Merck & Co.’s KEYTRUDA (Pembrolizumab) Compared To Chemotherapy In The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With High Levels Of PD-L1

  June 5, 2017

   · 

  21 min read
• Business

  Interpace Diagnostics Announces Agreement With Einstein Medical Center Of Philadelphia

  June 5, 2017

   · 

  6 min read
• Drug Development

  Novartis AG Landmark Study Of Tafinlar + Mekinist Demonstrates Durable Survival Benefit At Five Years In Patients With BRAF Mutation-Positive Metastatic Melanoma

  June 5, 2017

   · 

  15 min read
• Biotech Bay

  SentreHEART Amaze Trial Receives FDA Approval For Stage II Expansion Based On 100 Subject Interim Safety And Performance Analysis

  June 5, 2017

   · 

  4 min read
• Business

  Tilray Announces Medical Advisory Board

  June 5, 2017

   · 

  6 min read
• Biotech Bay

  Jaguar Animal Health And Napo Pharmaceuticals, Inc. Announce Filing Of Two Orphan Drug Designation Applications With FDA For Mytesi For Serious Unmet Medical Needs

  June 5, 2017

   · 

  9 min read
• Drug Development

  Peregrine Presents Preliminary Correlative Analysis Of PD-L1 Expression From SUNRISE Trial At ASCO 2017

  June 5, 2017

   · 

  6 min read
• Business

  Fortress Biotech Announces That Its Subsidiary, Mustang Bio, Enters Into License Agreements With City of Hope For Novel CAR T Immunotherapies

  June 5, 2017

   · 

  4 min read